These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17311836)

  • 41. Algorithms for the treatment of schizophrenia.
    Zarate CA; Daniel DG; Kinon BJ; Litman RE; Naber D; Pickar D; Sato M
    Psychopharmacol Bull; 1995; 31(3):461-7. PubMed ID: 8668750
    [No Abstract]   [Full Text] [Related]  

  • 42. An agent based force vector model of social influence that predicts strong polarization in a connected world.
    Maclay GJ; Ahmad M
    PLoS One; 2021; 16(11):e0259625. PubMed ID: 34784356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Econometric Modeling Of Individual And Social Multi-Attribute Utility Functions.
    Ford DL; Moskowitz H; Wittink DR
    Multivariate Behav Res; 1978 Jan; 13(1):77-97. PubMed ID: 26758484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The utility of thresholds and the threshold utility.
    Pauker SG; Pauker SP; Wong JB
    Med Decis Making; 1987; 7(4):201-2. PubMed ID: 3683106
    [No Abstract]   [Full Text] [Related]  

  • 45. Measuring utility of money through decisions.
    COOMBS CH; KOMORITA SS
    Am J Psychol; 1958 Jun; 71(2):383-9. PubMed ID: 13545411
    [No Abstract]   [Full Text] [Related]  

  • 46. The theory of utility.
    Rogers AE
    Science; 1886 Oct; 8(193):347-8. PubMed ID: 17782748
    [No Abstract]   [Full Text] [Related]  

  • 47. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
    Su P; Zhi K; Xu H; Xiao J; Liu J; Wang Z; Liu Q; Yu Y; Dang H
    Front Pharmacol; 2024; 15():1245825. PubMed ID: 38720775
    [No Abstract]   [Full Text] [Related]  

  • 48. Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
    Zhu R; Poland B; Wada R; Liu Q; Musib L; Maslyar D; Cho E; Yu W; Ma H; Jin JY; Budha N
    CPT Pharmacometrics Syst Pharmacol; 2019 Apr; 8(4):240-248. PubMed ID: 30762302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of infectious diseases and clinical microbiology specialists' preferences for hand hygiene: analysis using the multi-attribute utility theory and the analytic hierarchy process methods.
    Suner A; Oruc OE; Buke C; Ozkaya HD; Kitapcioglu G
    BMC Med Inform Decis Mak; 2017 Aug; 17(1):129. PubMed ID: 28859640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.
    Wagner M; Khoury H; Willet J; Rindress D; Goetghebeur M
    Pharmacoeconomics; 2016 Mar; 34(3):285-301. PubMed ID: 26547306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.
    De Fazio P; Girardi P; Maina G; Mauri MC; Mauri M; Monteleone P; Perini GI; Perugi G; Rossi A
    Clin Drug Investig; 2010; 30(12):827-841. PubMed ID: 20923242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of clinical utility assessments in early clinical development.
    Khan AA; Perlstein I; Krishna R
    AAPS J; 2009 Mar; 11(1):33-8. PubMed ID: 19145490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multiattribute decision model for bipolar disorder: identification of preferred mood-stabilizing medications.
    Suehs BT; Bettinger TL
    Am J Manag Care; 2009 Jul; 15(7):e42-52. PubMed ID: 19589006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sexual dysfunction in schizophrenia: focus on recent evidence.
    Baggaley M
    Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
    Vohora D
    Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
    Bettinger TL; Shuler G; Jones DR; Wilson JP
    Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.